Team

Vivek Kadambi, Ph.D., is an experienced pharmaceutical executive with more than 25 years of demonstrated results in all stages of drug discovery, development, registration and post marketing. Over his career, Dr. Kadambi was involved in numerous projects, including multiple first-in-class INDs, as well as the registration of multiple products, including ADCETRIS®, ENTYVIO®, AYVAKIT® and GAVRETO®. Dr. Kadambi previously served as the Chief Product Development Officer at IDRx, which was acquired by GSK in February 2025. Prior to this, he was the Senior Vice President of Preclinical Sciences at Vertex Pharmaceuticals. From 2014 to 2020, Dr. Kadambi held the position of Senior Vice President of Quantitative Pharmacology and Drug Safety at Blueprint Medicines (under agreement to be acquired by Sanofi). Dr. Kadambi also served as the Vice President of Drug Safety Evaluation at Millennium/Takeda. He was the recipient of the American Heart Association Fellowship, Ohio affiliate and the Young Investigator Award from the Heart Failure Society of America. He is the past chair of DruSafe, part of the International Consortium for Innovation and Quality in Pharmaceutical Development, and co-founder of the Boston Area Pharm/Tox group. Dr. Kadambi holds a Ph.D. in Cardiovascular Physiology and Pharmacology and a Post Doctoral degree in Cardiovascular Medicine from the University of Cincinnati College of Medicine.